Mukka Proteins shareholders approve ₹47 Crore preferential issue of warrants
Mukka Proteins shareholders approved the issuance of up to 2 crore warrants convertible into equity shares. The total issue size is ₹47 crore at ₹23.50 per warrant. The resolution was passed via postal ballot with a majority of votes in favor.
The preferential issuance of warrants for a significant amount (₹47 crore) can materially impact the company's capital structure, dilution, and future financial performance.
The company successfully passed a special resolution for a preferential issuance of warrants, indicating positive shareholder support for fundraising and potential future equity dilution.
Mukka Proteins Limited announced the successful passage of a special resolution through a postal ballot, authorizing the issuance of up to 2,00,00,000 (Two Crore) warrants convertible into equity shares on a preferential basis.
The total issue size for these warrants is ₹47,00,00,000 (Rupees Forty-Seven Crores Only), with each warrant priced at ₹23.50. Holders of these warrants will have the right to apply for and be allotted one fully paid-up equity share of face value ₹1 each at a premium of ₹22.50 per share. This conversion can be done within 18 months from the date of warrant allotment.
The postal ballot process, which involved remote e-voting, commenced on June 13, 2026, and concluded on July 12, 2026. The results were declared on July 14, 2026, with the special resolution being passed by the requisite majority. A total of 22,02,62,108 votes were cast, with 22,01,79,675 votes in favor of the resolution.
The issuance is in compliance with SEBI ICDR Regulations and will be offered to non-promoter category entities, including individuals like Mr. Irfan Chapra, Ms. Reshma Chapra, Mr. Vishal Maniar, and entities such as Multiplex Capital Limited. The company has authorized its Board to finalize terms and allot the warrants within 15 days of passing the resolution, subject to regulatory approvals.
What to do with a filing like this
Mukka Proteins Limited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mukka Proteins Limited. Read the original for the full detail.